A BILL FOR AN ACT

RELATING TO LIFE SCIENCES.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:

					4					
-	4	~~~~~	-1	CT 7	legislature	C ' - 7	1 7	1 7	7	The second secon
7		SECTION	1	'l'ne	learglature	Tings	That	The	IITA	CCIANCAC
- 3			<u> </u>	T 11	TCGTDTGCGTC		CIIC		\perp \perp \perp \sim	\mathcal{L}

- 2 industry plays a significant role in the diversification and,
- 3 therefore, the sustainability of Hawaii's economy. Ground-
- 4 breaking medical studies have already been conducted in Hawaii
- 5 by the Cancer Research Center and Pacific Health Research
- 6 Institute.
- 7 Hawaii's unique location and ethnic diversity provide
- 8 indispensable advantages to companies conducting clinical
- 9 trials. Life sciences companies that conduct these trials often
- 10 create more and higher paying jobs that will help to keep local
- 11 graduates employed in the State. In addition, conducting these
- 12 trials in Hawaii will put our State on the cutting edge of drug
- 13 development, bringing in research funding from Asia and North
- 14 America.
- 15 Providing a specific tax incentive to the life sciences
- 16 industry would particularly help Hawaii companies that are
- 17 pioneering pharmaceutical and other health products at a time

SB436 HD1 HMS 2009-3273

1	that they are entering phases three and four of their clinical			
2	trials.			
3	The purpose of this Act is to advance the important			
4	specialization components of the Hawaii life sciences industry			
5	by providing a tax incentive for life sciences companies to			
6	conduct clinical trials in Hawaii.			
7	SECTION 2. Chapter 235, Hawaii Revised Statutes, is			
8	amended by adding a new section to be appropriately designated			
9	and to read as follows:			
10	"§235- Clinical trials tax credit. (a) Any law to the			
11	contrary notwithstanding, there shall be allowed to each			
12	taxpayer subject to the taxes imposed by this chapter, a			
13	qualified clinical trial tax credit that shall be deductible			
14	from the taxpayer's net income tax liability, if any, imposed by			
15	this chapter for the taxable year in which the credit is			
16	properly claimed. The amount of the credit shall be:			
17	(1) Fifteen per cent of the qualified clinical trial costs			
18	incurred by a qualified clinical trial in any county			
19	of the State with a population that exceeds seven			
20	hundred thousand; or			
21	(2) Twenty per cent of the qualified clinical trial costs			
22	incurred by a qualified clinical trial in any county			

SB436 HD1 HMS 2009-3273

1	of the State with a population of seven hundred
2	thousand or less.
3	A qualified clinical trial occurring in more than one county may
4	prorate its expenditures based upon the amounts spent in each
5	county; provided that the population basis differs enough to
6	change the percentage of the tax credit.
7	In the case of a partnership, S corporation, estate, or
8	trust, the tax credit allowable is for qualified clinical trial
9	costs incurred by the entity for the taxable year. The cost
10	upon which the tax credit is computed shall be determined at the
11	entity level. Distribution and share of credit shall be
12	determined by rule.
13	If a deduction is taken under section 179 (with respect to
14	election to expense depreciable business assets) of the Internal
15	Revenue Code of 1986, as amended, no tax credit shall be allowed
16	for those costs for which the deduction is taken. The basis for
17	eligible property for depreciation of accelerated cost recovery
18	system purposes for state income taxes shall be reduced by the
19	amount of credit allowable and claimed.
20	(b) The credit allowed under this section shall be claimed
21	against the net income tax liability for the taxable year.

1	(C)	If the tax credit under this section exceeds the		
2	taxpayer'	s income tax liability, the excess of credits over		
3	liability	shall be refunded to the taxpayer; provided that no		
4	refunds o	r payment on account of the tax credits allowed by this		
5	section s	hall be made for amounts less than \$. All claims,		
6	including any amended claims, for tax credits under this section			
7	shall be filed on or before the end of the twelfth month			
8	following	the close of the taxable year for which the credit may		
9	be claime	d. Failure to comply with the foregoing provision		
10	shall con	stitute a waiver of the right to claim the credit.		
11	(d)	To qualify for this tax credit, a clinical trial		
12	shall:			
13	(1)	Meet the definition of a qualified clinical trial		
14		specified in subsection (1);		
15	(2)	Have qualified clinical trial costs totaling at least		
16		<u>\$</u> ;		
17	(3)	Provide evidence of reasonable efforts to hire local		
18		researchers and staff; and		
19	(4)	Provide evidence of financial or in-kind contributions		
20		or educational or workforce development efforts, in		
21		partnership with related trade and business		
22		development organizations, educational institutions,		

1	or both, toward the furtherance of the local science,
2	technology, and health industries.
3	(e) After June 30, 2009, no qualified clinical trial cost
4	that has been financed by investments for which a credit was
5	claimed by any taxpayer pursuant to sections 235-110.9 or 235-
6	110.91 shall be eligible for credits under this section.
7	(f) To receive the tax credit, the taxpayer shall first
8	pre-qualify the clinical trial for the credit by registering
9	with the department of business, economic development, and
10	tourism. Failure to comply with this provision may constitute a
11	waiver of the right to claim the credit.
12	(g) The director of taxation shall prepare forms as may be
13	necessary to claim a credit under this section. The director
14	may also require the taxpayer to furnish information to
15	ascertain the validity of the claim for the credit made under
16	this section and may adopt rules necessary to effectuate the
17	purposes of this section pursuant to chapter 91.
18	(h) Every taxpayer claiming a tax credit under this
19	section for a qualified clinical trial, no later than ninety
20	days following the end of each taxable year in which qualified
21	clinical trial costs were expended, shall submit a written,

1	sworn sta	tement to the department of business, economic		
2	developme	nt, and tourism, identifying:		
3	(1)	All qualified clinical trial costs under subsection		
4		(a), if any, incurred in the previous taxable year;		
5	(2)	The amount of tax credits claimed pursuant to this		
6		section, if any, in the previous taxable year; and		
7	(3)	The number of total hires versus the number of local		
8		hires by category (i.e., department) and by county.		
9	<u>(i)</u>	The department of business, economic development, and		
10	tourism shall:			
11	(1)	Maintain records of the names of the taxpayers and		
12	*	qualified clinical trials thereof claiming the tax		
13		credits under subsection (a);		
14	(2)	Obtain and total the aggregate amounts of all		
15		qualified clinical trial costs per trial and per		
16		taxable year; and		
17	(3)	Provide a letter to the director of taxation		
18		specifying the amount of the tax credit per qualified		
19		clinical trial for each taxable year that a tax credit		
20		is claimed and the cumulative amount of the tax credit		
21		for all years claimed.		

- 1 Upon each determination required under this subsection, the
- 2 department of business, economic development, and tourism shall
- 3 issue a letter to the taxpayer regarding the qualified clinical
- 4 trial, specifying the qualified clinical trial costs and the tax
- 5 credit amount qualified for in each taxable year a tax credit is
- 6 claimed. The taxpayer for each qualified clinical trial shall
- 7 file the letter with the taxpayer's tax return to the department
- 8 of taxation. Notwithstanding the authority of the department of
- 9 business, economic development, and tourism under this section,
- 10 the director of taxation may audit and adjust the tax credit
- 11 amount to conform to the information filed by the taxpayer.
- 12 (j) Total tax credits claimed per qualified clinical trial
- 13 shall not exceed \$.
- 14 (k) Qualified clinical trials shall comply with
- 15 subsections (d), (e), (f), and (h).
- 16 (1) No taxpayer that claims the credit under this section
- 17 shall claim any other tax credit under this chapter for the same
- 18 taxable year.
- 19 (m) For the purposes of this section:
- 20 "Qualified clinical trial" means a research study conducted
- 21 within the State, to answer specific questions about vaccines,
- 22 new therapies, or new ways of using known treatments to

SB436 HD1 HMS 2009-3273



- 1 determine whether these new drugs or treatments are both safe 2 and effective. "Qualified clinical trial costs" means the costs incurred 3 by a qualified clinical trial within the State that are subject 4 5 to the general excise tax under chapter 237 or income tax under this chapter and that have not been financed by any investments 6 7 for which a credit was or will be claimed pursuant to section 235-110.9 or 235-110.91. Qualified clinical trial costs include 8 9 but are not limited to: 10 Costs associated with planning, designing, executing, (1) and analyzing a qualified clinical trial; 11 12 (2) Data, blood, and tissue sampling and analysis, and 13 statistical analysis; Hospital, physician, and nursing costs; 14 (3) 15 (4)Wages or salaries of researchers and staff; 16 (5) Costs of imaging and related technical services; 17 (6) Costs associated with clinical trial participants; 18 (7) Rentals and fees for use of local facilities and 19 research laboratories; and (8) 20 Other direct clinical trial costs specified by the 21 department of taxation." 22 SECTION 3. New statutory material is underscored.
 - SB436 HD1 HMS 2009-3273

- 1 SECTION 4. This Act shall take effect on July 1, 2020 and
- 2 shall apply to taxable years beginning after December 31, 2020.

Report Title:

Clinical Trials; Tax Credit

Description:

Provides for an income tax credit amounting to 15 per cent of qualified clinical trial costs incurred, in any county with a population over 700,000, and 20 per cent in any county with a population of 700,000 or less. Establishes criteria to qualify for the tax credit. Caps credit at \$ per clinical trial. (SB436 HD1)